GAITHERSBURG, Maryland, August 28, 2026, 12:16 (EDT)
- Novavax stock was at $9.00, falling 0.6% following the update on three-market approval.
- Sanofi’s sales may produce royalties ranging from the high teens up to the low twenties percent.
- Novavax’s 2026 revenue outlook does not include those royalties and milestones connected to Sanofi.
Novavax, Inc. (NASDAQ: NVAX) announced that its partners secured regulatory clearance for the XFG-adapted Nuvaxovid vaccine in the United States, European Union and Japan. Shares dipped 0.6% to $9.00 as of 11:58 a.m. EDT.
The muted action turns focus from regulatory approval towards commercial uptake. Novavax is now mainly reliant on partners for selling the shot and providing royalties.
Sanofi (NASDAQ: SNY) heads up the commercialization of Nuvaxovid in the majority of big markets. Novavax stands to receive royalties ranging from the high teens up to the low twenties percent from Sanofi’s worldwide net sales.
This arrangement keeps Novavax’s selling costs low but takes away its direct influence over demand. Sanofi is expanding in the U.S. and rolling out launches in Germany, Canada and additional markets.
Takeda markets Nuvaxovid in Japan. Novavax reported the vaccine was the second most used in the country for the 2025-2026 season, with higher delivery volumes and more sites involved.
| Company | U.S. price | Session move | 2026-2027 vaccine role |
|---|---|---|---|
| Novavax | $9.00 | -0.6% | Protein vaccine platform; receives royalties |
| Moderna | $137.12 | -4.0% | Updated mRNA-based vaccines |
| Pfizer | $27.93 | -0.3% | New mRNA vaccine co-developed with BioNTech |
| Sanofi ADR | $44.82 | Flat | Primary commercial partner for Nuvaxovid in leading markets |
The FDA has cleared updated vaccines from Novavax-Sanofi, Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE)-BioNTech. The newly approved shots are formulated to protect against the leading XFG variant.
Nuvaxovid is still the protein-based option among available vaccines. The reformulated vaccine contains Novavax’s Matrix-M adjuvant and comes in pre-filled syringes that must be kept at 2°C to 8°C.
Royalties have the potential to significantly impact the revenue composition. Novavax’s adjusted 2026 forecast of $235 million to $275 million does not factor in Sanofi supply sales, royalties, or milestone payments.
Revenue for the second quarter reached $57 million, representing a 76% decline compared to a prior year that included significant milestones. Product sales increased by 76% to $19 million, and cash stood at $724 million.
The company anticipates providing commercial supply to Sanofi for this season. A scheduled manufacturing transfer in mid-2027 may activate an additional $75 million milestone payment.
Analyst opinions are varied. The latest four ratings include two buys, a hold, and a sell, with price targets ranging between $7 and $19.
Risks are still significant. Seasonal demand, insurance coverage, and partner performance will influence royalty revenues, and Novavax did not offer a sales outlook from Sanofi.
While approvals eliminate a regulatory hurdle for investors, uncertainty around demand remains. The next key indicator will be disclosed partner sales and the resulting royalty revenue.
Related articles: NYSE:PFE
